Financial Summary for the Fiscal Year Ending March 2026 [Japanese Standards] (Consolidated)

Performance Overview

For the fiscal year ending March 2026, consolidated net sales were ¥126.257 billion (a decrease of 2.9% YoY). While sales of new pharmaceuticals (domestic) increased by 3.5%, the sales decline was offset by a reactionary decrease in contract up-front payments for new pharmaceuticals (overseas) and an increase in generic drug sales, resulting in overall revenue decline. Operating income was ¥3.567 billion (down 71.6%), ordinary income was ¥4.031 billion (down 69.5%), and net income attributable to owners of the parent was ¥3.448 billion (down 62.0%), reflecting significant profit decrease. R&D expenses increased by 14.7% to ¥12.060 billion, emphasizing efforts to expand the pipeline of new drugs.

Financial Position and Cash Flows

Total assets increased by ¥1.836 billion from the previous year to ¥195.455 billion. Net assets rose by 2.5 percentage points to ¥142.425 billion, with the equity ratio standing at 72.9%. Cash flows from operating activities generated ¥6.381 billion, investing activities used ¥1.644 billion, and financing activities used ¥7.956 billion, resulting in a cash and cash equivalents balance of ¥11.802 billion at period-end.

Earnings Forecast for Next Fiscal Year

For the fiscal year ending March 2027, consolidated earnings are forecasted to be ¥121.8 billion (down 3.5% YoY) in net sales, ¥2.0 billion (down 43.9%) in operating income, ¥2.3 billion (down 42.9%) in ordinary income, and ¥1.5 billion (down 56.5%) in net income attributable to owners of the parent. The forecast assumes an exchange rate of 1 USD = ¥152 and 1 EUR = ¥179.